Skip to main content
SpringerLink
Log in

201Thallium SPECT and 1H-MRS Compared with MRI in Chemotherapy Monitoring of High-grade Malignant Astrocytomas

  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

Purpose To compare chemotherapy treatment monitoring in astrocytoma by 201thallium single photon emission computed tomography (SPECT) and photon magnetic resonance spectroscopy (1H-MRS) with magnetic resonance imaging (MRI), and to evaluate the influence of morphological tumor changes on cerebral 201thallium uptake and metabolic changes in 1H-MRS.

Materials and methods Six patients with highly malignant astrocytomas were followed with quantitative 201thallium SPECT, MRI, and 1H-MRS during chemotherapy. Maximum follow-up included six examinations per patient by either method during 18 months. Criteria were set for: (1) regression (≥ 25% tumor reduction), (2) status quo (< 25% reduction and < 25% increase), and (3) progression of disease (≥ 25% tumor increase). Results were compared with the clinical state of disease. Changes of tumor volume, contrast enhancement, necrosis, hemorrhage and edema on MRI were compared to changes in 201thallium uptake volumes and 1H-MRS metabolite ratios.

Results Six patients were followed with a total of twenty-four examinations with 201thallium SPECT, MRI and 1H-MRS, respectively, between February 1997 and October 1998. Five patients developed clinical progression of disease, 4 out of 5 cases showed SPECT progression, 4 out of 5 cases MRI progression, and 1 out of 2 interpretable cases 1H-MRS progression at final assessment before clinical deterioration. During the phase of clinically stable disease; (A) the criterion for regression or status quo was met in 10 out of 13 assessments with SPECT, 11 out of 13 with MRI, and 8 out of 9 interpretable 1H-MRS; (B) the criterion for progression was met in 3 out of 13 with SPECT, 2 out of 13 with MRI, and 1 out of 9 interpretable 1H-MRS. The accuracy of SPECT, MRI, and 1H-MRS in identifying changes of tumor burden concordant with patients' clinical course was 78%, 83%, and 82%, respectively. SPECT regression was associated with MRI decrease of tumor size, contrast enhancement, edema and hemorrhage. SPECT progression was associated with MRI increase of the same parameters and the increase of necrosis. 1H-MRS regression was associated with decrease of edema. 1H-MRS progression was associated with increase of tumor size, hemorrhage, and increase or decrease of contrast enhancement.

Conclusions Both 201thallium SPECT and 1H-MRS evaluation showed sensitivity for detection of astrocytoma progression. We did not find a higher accuracy of SPECT or MRS than of MRI in astrocytoma chemotherapy monitoring. Treatment induced MRI changes were associated with 201thallium uptake variations. 1H-MRS was difficult to apply for astrocytoma treatment monitoring. Improvements regarding size of measurement area such as multivoxel MRS and fat suppression pulses appeared desirable, and also the use of functional techniques with superior resolution such as dual isotope SPECT. However, our results suggest that 201thallium SPECT and 1H-MRS can provide additional information to MRI for chemotherapy efficacy evaluation in selected cases.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Byrne TN: Imaging of gliomas. Semin Oncol 21(2): 162-171, 1994

    Google Scholar 

  2. Kaplan RS: Complexities, pitfalls, and strategies for evaluating brain tumor therapies. Curr Opin Oncol 10(3): 175-178, 1998

    Google Scholar 

  3. Perry JR, DeAngelis LM, Schold SC, Jr., Burger PC, Brem H, Brown MT et al.: Challenges in the design and conduct of phase III brain tumor therapy trials. Neurology 49(4): 912-917, 1997

    Google Scholar 

  4. Cairncross JG, Pexman JH, Rathbone MP, DelMaestro RF: Postoperative contrast enhancement in patients with brain tumor. Ann Neurol 17(6): 570-572, 1985

    Google Scholar 

  5. Tamura M, Shibasaki T, Zama A, Kurihara H, Horikoshi S, Ono N et al.: Assessment of malignancy of glioma by positron emission tomography with 18F-fluorodeoxyglucose and single photon emission computed tomography with thallium-201 chloride. Neuroradiology 40(4): 210-251, 1998

    Google Scholar 

  6. Taguchi A: Clinical significance of thallium-201 singlephoton emission computerized tomography (Tl-201 SPECT) in the evaluation of viability of gliomas. Kurume Med J 39(4): 267-278, 1992

    Google Scholar 

  7. Kim KT, Black KL, Marciano D, Mazziotta JC, Guze BH, Grafton S et al.: Thallium-201 SPECT imaging of brain tumors: methods and results. J Nucl Med 31(6): 965-969, 1990

    Google Scholar 

  8. Rodrigues M, Fonseca AT, Salgado D, Vieira MR: 99Tcm-HMPAO brain SPECT in the evaluation of prognosis after surgical resection of astrocytoma. Comparison with other noninvasive imaging techniques (CT, MRI and 201Tl SPECT). Nucl Med Commun 14(12): 1050-1060, 1993

    Google Scholar 

  9. Mountz JM, Stafford-Schuck K, McKeever PE, Taren J, Beierwaltes WH: Thallium-201 tumor/cardiac ratio estimation of residual astrocytoma. J Neurosurg 68(5): 705-709, 1998

    Google Scholar 

  10. Waldrop SM, Davis PC, Padgett CA, Shapiro MB, Morris R: Treatment of brain tumors in children is associated with abnormal MR spectroscopic ratios in brain tissue remote from the tumor site (see comments). AJNR Am J Neuroradiol 19(5): 963-970, 1998

    Google Scholar 

  11. Preul MC, Leblanc R, Caramanos Z, Kasrai R, Narayanan S, Arnold DL: Magnetic resonance spectroscopy guided brain tumor resection: differentiation between recurrent glioma and radiation change in two diagnostically difficult cases. Can J Neurol Sci 25(1): 13-22, 1998

    Google Scholar 

  12. Speck O, Thiel T, Hennig J: Grading and therapy monitoring of astrocytomas with 1H-spectroscopy: preliminary study. Anticancer Res 16(3B): 1581-1585, 1996

    Google Scholar 

  13. Houkin K, Kamada K, Sawamura Y, Iwasaki Y, Abe H, Kashiwaba T: Proton magnetic resonance spectroscopy (1H-MRS) for the evaluation of treatment of brain tumors. Neuroradiology 37(2): 99-103, 1995

    Google Scholar 

  14. Kernohan JW, Mabon RF, Svein HJ, Adson AW: A simplified classification of gliomas. Proc Staff Meet Mayo Clinic 24: 71-75, 1949

    Google Scholar 

  15. Sandberg-Wollheim M, Malmstrom P, Stromblad LG, Anderson H, Borgstrom S, Brun A et al.: A randomized study of chemotherapy with procarbazine, vincristine, and lomustine with and without radiation therapy for astrocytoma grades 3 and/or 4. Cancer 68(1): 22-29, 1991

    Google Scholar 

  16. Sjoholm H, Elmqvist D, Rehncrona S, Rosen I, Salford LG: SPECT imaging of gliomas with Thallium-201 and Technetium-99m-HMPAO. Acta Neurol Scand 91(1): 66-70, 1995

    Google Scholar 

  17. Ueda T, Kaji Y, Wakisaka S, Watanabe K, Hoshi H, Jinnouchi S et al.: Time sequential single photon emission computed tomography studies in brain tumor using thallium-201. Eur J Nucl Med 20(2): 138-145, 1993

    Google Scholar 

  18. Black KL, Hawkins RA, Kim KT, Becker DP, Lerner C, Marciano D: Use of thallium-201 SPECT to quantitate malignancy grade of gliomas. J Neurosurg 71(3): 342-346, 1989

    Google Scholar 

  19. Kallen K, Geijer MD, Andersson AM, Holtas S, Ryding E, Rosen I: Glioma viability assessment by Thallium-201 SPECT Tumor Uptake Volume (TUV) estimation. J Nucl Med Comm 1999 (in press)

  20. Yoshii Y, Satou M, Yamamoto T, Yamada Y, Hyodo A, Nose T et al.: The role of thallium-201 single photon emission tomography in the investigation and characterisation of brain tumors in man and their response to treatment. Eur J Nucl Med 20(1): 39-45, 1993

    Google Scholar 

  21. Carvalho PA, Schwartz RB, Alexander E, III, Garada BM, Zimmerman RE, Loeffler JS et al.: Detection of recurrent gliomas with quantitative thallium-201/technetium-99m HMPAOsingle-photon emission computerized tomography. J Neurosurg 77(4): 565-570, 1992

    Google Scholar 

  22. Zhang JJ, Park CH, Kim SM, Ayyangar KM, Haghbin M: Dual isotope SPECT in the evaluation of recurrent brain tumor. Clin Nucl Med 17(8): 663-664, 1992

    Google Scholar 

  23. Moustafa HM, Omar WM, Ezzat I, Ziada GA, el Ghonimy EG: 201Tl single photon emission tomography in the evaluation of residual and recurrent astrocytoma. Nucl Med Commun 15(3): 140-143, 1994

    Google Scholar 

  24. Schwartz RB, Carvalho PA, Alexander F, III, Loeffler JS, Folkerth R, Holman BL: Radiation necrosis vs high-grade recurrent glioma: differentiation by using dual-isotope SPECT with 201Tl and 99mTc-HMPAO. AJNR Am J Neuroradiol 12(6): 1187-1192, 1991

    Google Scholar 

  25. Sonoda Y, Kumabe T, Takahashi T, Shirane R, Yoshimoto T: Clinical usefulness of 11C-MET PET and 201Tl SPECT for differentiation of recurrent glioma from radiation necrosis. Neurol Med Chir (Tokyo) 38(6): 342-347, 1998

    Google Scholar 

  26. Lorberboym M, Baram J, Feibel M, Hercbergs A, Lieberman L: A prospective evaluation of thallium-201 single photon emission computerized tomography for brain tumor burden. Int J Radiat Oncol Biol Phys 32(1): 249-254, 1995

    Google Scholar 

  27. DeAngelis LM. Brain tumor therapy: new horizons, new hope (editorial; comment). Neurology 50(5): 1209-1210, 1998

    Google Scholar 

  28. DeAngelis LM, Burger PC, Green SB, Cairncross JG: Malignant glioma: who benefits from adjuvant chemotherapy? Ann Neurol 44(4): 691-695, 1998

    Google Scholar 

  29. Bloom M, Jacobs S, Pile-Spellman J, Pozniakoff A, Mabutas MI, Fawwaz RA et al.: Cerebral SPECT imaging: effect on clinical management. J Nucl Med 37(7): 1070-1073, 1993

    Google Scholar 

  30. Kallen K, Heiling M, Andersson AM, Brun A, Holtas S, Ryding E: Preoperative grading of glioma malignancy with thallium-201 single-photon emission CT: comparison with conventional CT. AJNR Am J Neuroradiol 17(5): 925-932, 1996

    Google Scholar 

  31. Kimura H, Takeno Y, Fukushima T: Variation in appearance ofglioma on serial thallium-201 single photon emission computed tomography-case report. Neurol Med Chir (Tokyo) 35(5): 317-320, 1995

    Google Scholar 

  32. Kallen K, Heiling M, Andersson AM, Brun A, Holtas S, Ryding E et al.: Evaluation of malignancy in ring enhancing brain lesions on CT by thallium-201 SPECT. J Neurol Neurosurg Psychiatry 63(5): 569-574, 1997

    Google Scholar 

  33. Ricci M, Pantano P, Pierallini A, Di Stefano D, Santoro A, Bozzao L et al.: Relationship between thallium-201 uptake by supratentorial glioblastomas and their morphological characteristics on magnetic resonance imaging. Eur J Nucl Med 23(5): 524-529, 1996

    Google Scholar 

  34. Nadvi SS, Ebrahim FS, Corr P: The value of 201thallium-SPECT imaging in childhood brainstem gliomas. Pediatr Radiol 28(8): 575-579, 1998

    Google Scholar 

  35. Namba H, Togawa T, Yui N, Yanagisawa M, Kinoshita F, Iwadate Y et al.: The effect of steroid on thallium-201 uptake by malignant gliomas. Eur J Nucl Med 23(8): 991-992, 1996

    Google Scholar 

  36. Luyten PR, Marien AJ, Heindel W, van Gerwen PH, Herholz K, den Hollander JA et al.: Metabolic imaging of patients with intracranial tumors: H-1 MR spectroscopic imaging and PET. Radiology 176(3): 791-799, 1990

    Google Scholar 

  37. Segebarth CM, Baleriaux DF, Luyten PR, den Hollander JA: Detection of metabolic heterogeneity of human intracranial tumors in vivo by 1H NMR spectroscopic imaging. Magn Reson Med 13(1): 62-76, 1990

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, University Hospital, Lund, Sweden

    K. Källén

  2. Department of Neuroradiology, University Hospital, Lund, Sweden

    I.M. Burtscher, S. Holtås, E. Ryding & I. Rosén

Authors
  1. K. Källén
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. I.M. Burtscher
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S. Holtås
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. E. Ryding
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. I. Rosén
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Källén, K., Burtscher, I., Holtås, S. et al. 201Thallium SPECT and 1H-MRS Compared with MRI in Chemotherapy Monitoring of High-grade Malignant Astrocytomas. J Neurooncol 46, 173–185 (2000). https://doi.org/10.1023/A:1006429329677

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1006429329677

Search

Navigation